All In Biotech

Drug Trial Radar · NCT04452591

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG)

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Oct 27, 2020

Primary completion

Jun 16, 2030

Study completion Dec 24, 2031

Sponsor

Lead sponsor
CG Oncology, Inc.Industry
Sponsor type
Industry
First posted
Jun 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC

Conditions

  • Non Muscle Invasive Bladder Cancer
  • High-grade Ta/ T1 Papillary Disease Bladder Cancer

Interventions

  • Cretostimogene GrenadenorepvecBiological

    Engineered Oncolytic Adenovirus

  • n-dodecyl-B-D-maltosideOther

    Transduction-enhancing agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort C:Time frame: 36 months
  2. Cohort P:Time frame: 36 months

Locations

86 sites in 6 countries. Site status is shown where the registry gives one.

  • Urology Centers Alabama

    Homewood, Alabama

  • BCG Oncology

    Phoenix, Arizona

  • Mayo Clinic Cancer Center

    Phoenix, Arizona

  • Arizona Institute of Urology

    Tucson, Arizona

  • Arkansas Urology

    Little Rock, Arkansas

  • University of California - Irvine

    Irvine, California

  • American Insititute of Research

    Los Angeles, California

  • Genesis Research

    Sherman Oaks, California

  • Genesis Research LLC

    Torrance, California

  • University of Colorado

    Aurora, Colorado

  • Colorado Clinical Research

    Lakewood, Colorado

  • Urology Associates, Research Department

    Lone Tree, Colorado

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Moffit Cancer Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Urology Indiana LLC

    Greenwood, Indiana

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Wichita Urology

    Wichita, Kansas

  • Southern Urology

    Lafayette, Louisiana

  • Chesapeake Urology

    Hanover, Maryland

  • Chesapeake Urology

    Severna Park, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Mayo Rochester

    Rochester, Minnesota

  • Mercy Medical Center

    St Louis, Missouri

  • Washington University

    St Louis, Missouri

  • Specialty Clinical Research of St. Louis

    St Louis, Missouri

  • New Jersey Premier Urology

    Edison, New Jersey

  • Our Lady of Lourdes

    Binghamton, New York

  • Stony Brook University

    Stony Brook, New York

  • Montifiore Medical Center

    The Bronx, New York

  • Duke University

    Durham, North Carolina

  • Wake Forest

    Winston-Salem, North Carolina

  • University of Toledo

    Toledo, Ohio

  • Keystone Urology Specialists

    Lancaster, Pennsylvania

  • University of Pennsylvania, Perelman School of Medicine

    Philadelphia, Pennsylvania

  • Prisma Health - Regional Urology

    Greenville, South Carolina

  • Carolina Urologic Research Center LLC

    Myrtle Beach, South Carolina

  • Conrad Pearson Clinic

    Germantown, Tennessee

  • Urology Associates- Nashville

    Nashville, Tennessee

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.